Magellan Stem Cells
Sydney, Australia
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (4)
○ EMA GMP
○ MHRA GMP
Quick Facts: Magellan Stem Cells
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Sydney, Australia
- Modalities
- Cell Therapy, MSC, CAR-T, NK Cell, iPSC, Exosome, Fibroblast
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Magellan Stem Cells
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy, MSC, CAR-T, NK Cell, iPSC, Exosome, Fibroblast
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press4 articles
Broad modality coverage (7 modalities)
Recent News 4 articles
Australian Research Shows That Stem Cell Therapy Improves Quality of Life by More Than 290% for Osteoarthritis Sufferers - PR Newswire
$7 million grant for groundbreaking osteoarthritis research utilising stem cell therapy - Charles Sturt University
Animal Regenerative Therapies Market Worldwide to Reach USD 870 Million by 2032, Driven by Advancements in Veterinary Biotechnology | Vyansa Intelligence - PR Newswire UK
Stem cell marvel to replace surgery - Herald Sun
Frequently Asked Questions About Magellan Stem Cells
What is Magellan Stem Cells's CDMO Signal Score?
Magellan Stem Cells has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Magellan Stem Cells for a manufacturing program?
Use the free AI matchmaker to compare Magellan Stem Cells against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Cellipont Bioservices
The Woodlands, TX
Cell Therapy, CAR-T, MSC, iPSC, Exosome, Autologous, Allogeneic
RoslinCT
Edinburgh, UK · Hopkinton, MA
Signal Score: 80.2
CAR-T, Cell Therapy, iPSC, Gene Editing
Cell Therapies Pty Ltd
Melbourne, Australia
Signal Score: 59.0
Cell Therapy, CAR-T
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 90.8
CAR-T, Cell Therapy